ArticleCureus2025
Diagnostic Value of Biochemical Markers in the Preoperative and Intraoperative Verification of Biliary Fistulas in Liver Echinococcosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study evaluates the prognostic significance of biochemical markers in diagnosing biliary fistulas (BF) in liver echinococcosis (LE). Methods The study included 85 patients with LE who underwent surgery between 2021 and 2024. Among them, 24 had BF (11 men, 13 women, mean age 40.5±14), and 61 had no BF (27 men, 34 women, mean age 38±13.4). Cysts were classified by WHO-IWGE criteria. Biochemical markers (total and conjugated bilirubin, ALP, GGT, ALT, AST, leukocyte count, eosinophils) were analyzed in blood and cyst contents. Statistical analysis used independent t-tests (p<0.05). Results Preoperative blood analysis showed no significant differences in bilirubin, ALP, GGT, ALT, AST, or leukocyte count between groups (p>0.05). However, eosinophil levels were significantly higher in the BF group (5.8±3.8% vs. 3.7±2.9%, p=0.0184). Cyst content analysis revealed significantly higher total bilirubin in BF cysts (28.8±21.4 µmol/L) versus non-BF cysts (1.2±0.9 µmol/L, p=0.00002). Conjugated bilirubin was also higher (16±15.3 µmol/L vs. 0.1±0.3 µmol/L, p=0.00018), while ALP and GGT showed no significant differences (p>0.05). Subgroup analysis (CE1-2 vs. CE3) showed no significant differences in biochemical markers between BF and non-BF groups (p>0.05), except eosinophils, which were higher in the BF group (p=0.0080). In CE1-2, occult BF cysts had higher total bilirubin than non-BF cysts (6±3.7 µmol/L vs. 1.2±1 µmol/L, p=0.0132). In CE3, total bilirubin was also significantly higher in BF cysts (p=0.00002). Further analysis showed that total bilirubin in obvious BF was 41±15.9 µmol/L, significantly higher than in occult BF (6±3.7 µmol/L, p<0.00001). Conclusion Biochemical analysis of cyst contents is superior to blood markers for BF verification. Total bilirubin in cyst contents had 100% specificity and 92.0% accuracy, with sensitivity increasing from 60.0% to 95% at a threshold of 2.6 µmol/L. Blood markers, including bilirubin and GGT, had limited diagnostic value. Elevated eosinophils (p=0.0184) were the only significant blood marker but lacked sufficient sensitivity (58.3%) and specificity (72.1%) for reliable preoperative diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.